Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes

We of course welcome the fact that the issue of obesity and diabetes in the management of psychosis is taken seriously by the disciplines represented in this conference (1). However, as clinical psychiatrists we are concerned that some of the matters raised may give an unintentionally misleading message. We are far from sure, for example, that the evidence supports the view that there is so much disparity in the incidence of obesity and diabetes among first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs). Furthermore, there is no evidence, for that matter, of disparity …